510(k) device
MECTA Sigma
Mecta Corporation · Electroconvulsive Therapy Device For Catatonia, Major Depressive Disorder, And Bipolar Disorder (QGH, Class II) · First FDA decision Apr 26, 2020, newest Apr 26, 2020DepressionOCD, PTSD and other psychiatric conditions
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
3
Naming "MECTA Sigma"
MAUDE reports
2
Brand "MECTA Sigma", since 2015
PubMed studies
0
Mentioning "MECTA Sigma"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing MECTA Sigma
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- MECTA Sigma510(k)
K192834 · Decided Apr 26, 2020 · 207 days after receipt
Device type: Electroconvulsive Therapy Device For Catatonia, Major Depressive Disorder, And Bipolar Disorder (QGH) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34522First Coast Service Options, Inc.Updated Oct 21, 2022
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34998Novitas Solutions, Inc.Updated Oct 21, 2022
- Fluidized Therapy Dry Heat for Certain Musculoskeletal DisordersNational determinationOn the books150.8Updated Apr 17, 2020
- Multiple-Seizure Electroconvulsive TherapyNational analysisReview closedCAG-00134NUpdated Sep 15, 2026
- Treatment of Motor Function Disorders with Electric Nerve StimulationNational determinationOn the books160.2Updated Aug 17, 2023
- Multiple Electroconvulsive Therapy (MECT)National determinationOn the books160.25Updated Oct 1, 2015
- Hospice Alzheimer's Disease & Related DisordersLocal determinationIn effectL34567Palmetto GBAUpdated Feb 23, 2024
- Speech - Language Pathology (SLP) Services: Communication DisordersLocal determinationIn effectL35070Novitas Solutions, Inc.Updated Aug 6, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "MECTA Sigma", any status and sponsor, newest update first.
Centre for Addiction and Mental HealthAcademic, hospital or other
NCT06672588 · 80 participants (planned) · Start Apr 22, 2025 · Primary completion Nov 2028
Device: Magnetic Seizure Therapy (MST); Electroconvulsive Therapy (ECT) · For: Treatment Resistant Schizophrenia; Schizophrenia; Schizoaffective Disorder
Sites: Vancouver, Canada; Toronto, Canada
- Efficacy of Convulsive Therapies During ContinuationPivotal-lookingCompleted
Centre for Addiction and Mental HealthAcademic, hospital or other
NCT03711019 · 106 participants · Start Oct 22, 2018 · Primary completion Oct 10, 2024
Device: Magnetic Seizure Therapy (MST); RUL-UB ECT and 1 more · For: Depression; Bipolar Depression; Unipolar Depression and 1 more
Sites: Vancouver, Canada; Toronto, Canada; Whitby, Canada
Centre for Addiction and Mental HealthAcademic, hospital or other
NCT03641300 · 76 participants · Start Sep 21, 2018 · Primary completion Mar 4, 2024
Device: Magnetic Seizure Therapy (MST); Electroconvulsive Therapy (ECT) · For: Bipolar Disorder; Bipolar Depression; Bipolar I Disorder and 1 more
Sites: Vancouver, Canada; Toronto, Canada; Whitby, Canada
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "MECTA Sigma", and for the whole product code for context.
This brand
2 reports: 0 malfunction, 2 injury, 0 death
Whole product code QGH
35 reports: 1 malfunction, 33 injury, 1 death
Newest reports for this brand
- MECTA SIGMAInjury
3020533-2024-00001 · Received Feb 29, 2024 · Event dated Jun 23, 2023 · 1 other device named on this report
Device type: Electroconvulsive Therapy Device For Catatonia, Major Depressive Disorder, And Bipolar Disorder (QGH)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Chest Pain; Headache; Pain; Fecal Incontinence
- MECTA SIGMA ECTInjury
MW5150099 · Received Jan 9, 2024 · Event dated Jun 23, 2023
Device type: Device, Electroconvulsive Therapy (GXC)
Device problem as coded: Improper or Incorrect Procedure or Method
Patient problem as coded: Chest Pain; Headache; Pain; Fecal Incontinence
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "MECTA Sigma"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.